Bibliography
- Matsuo H, Baba Y, Nair RM, Structure of the porcine LH- and FSH-releasing hormone. I. The proposed amino acid sequence. Biochem Biophys Res Commun 1971;43:1334-9
- Kastin AJ, Coy DH, Schally AV, Zadina JE. Dissociation of effects of LH-RH analogs on pituitary regulation and reproductive behavior. Pharmacol Biochem Behav 1980;13:913-4
- Carmel PW, Araki S, Ferin M. Pituitary stalk portal blood collection in rhesus monkeys: evidence for pulsatile release of gonadotropin-releasing hormone (GnRH). Endocrinology 1976;99:243-8
- Redding TW, Kastin AJ, Gonzales-Barcena D, The half-life, metabolism and excretion of tritiated luteinizing hormone-releasing hormone (LH-RH) in man. J Clin Endocrinol Metab 1973;37:626-31
- Belchetz PE, Plant TM, Nakai Y, Hypophysial responses to continuous and intermittent delivery of hypopthalamic gonadotropin-releasing hormone. Science 1978;202:631-3
- Schultze-Mosgau A, Griesinger G, Altgassen C, New developments in the use of peptide gonadotropin-releasing hormone antagonists versus agonists. Expert Opin Investig Drugs 2005;14:1085-97
- Millar RP. GnRHs and GnRH receptors. Anim Reprod Sci 2005;88:5-28
- Schally AV, Nagy A. New approaches to treatment of various cancers based on cytotoxic analogs of LHRH, somatostatin and bombesin. Life Sci 2003;72:2305-20
- Padula AM. GnRH analogues – agonists and antagonists. Anim Reprod Sci 2005;88:115-26
- Coccia ME, Comparetto C, Bracco GL, Scarselli G. GnRH antagonists. Eur J Obstet Gynecol Reprod Biol 2004;115S:44-56
- Huirne JA, Homburg R, Lambalk CB. Are GnRH antagonists comparable to agonists for use in IVF? Hum Reprod 2007;22:2805-13
- Reissmann T, Schally AV, Bouchard P, The LHRH antagonist cetrorelix: a review. Hum Reprod Update 2000;6:322-31
- Trachtenberg J. Emerging pharmacologic therapies for prostate cancer. Rev Urol 2001;3:S23-8
- Schmidt F, Sundaram K, Thau RB, Bardin CW. [Ac-D-NAL(2)1,4FD-Phe2,D-Trp3,D-Arg6]-LHRH, a potent antagonist of LHRH, produces transient edema and behavioral changes in rats. Contraception 1984;29:283-9
- Bajusz S, Csernus VJ, Janáky T, New antagonists of LHRH. II. Inhibition and potentiation of LHRH by closely related analogues. Int J Pept Protein Res 1988;32:425-35
- Cook T, Sheridan WF. Development of GnRH antagonists for prostate cancer: new approaches to treatment. Oncologist 2000;5:162-8
- Nestor JJ Jr, Tahilramani R, Ho TL, Potent gonadotropin releasing hormone antagonists with low histamine-releasing activity. J Med Chem 1992;35:3942-8
- Jiang G, Stalewski J, Galyean R, GnRH antagonists: a new generation of long acting analogues incorporating p-ureido-phenylalanines at positions 5 and 6. J Med Chem 2001;44:453-67
- Deghenghi R, Boutignon F, Wüthrich P, Lenaerts V. Antarelix (EP 24332) a novel water soluble LHRH antagonist. Biomed Pharmacother 1993;47:107-10
- Beckers T, Bernd M, Kutscher B, Structure-function studies of linear and cyclized peptide antagonists of the GnRH receptor. Biochem Biophys Res Commun 2001;289:653-63
- Janecka A, Janecki T, Shan S, Novel, potent luteinizing hormone-releasing hormone antagonists withis in water. J Med Chem 1994;37:2238-41
- Phillips A, Hahn DW, McGuire JL, Evaluation of the anaphylactoid activity of a new LHRH antagonist. Life Sci 1988;43:883-8
- Rivier JE, Jiang G, Porter J, Gonadotropin-releasing hormone antagonists: novel members of the azaline B family. J Med Chem 1995;38:2649-62
- Rivier J, Porter J, Hoeger C, Gonadotropin-releasing hormone antagonists with N- omega-triazolylornithine, -lysine, or -p-aminophenylalanine residues at positions 5 and 6. J Med Chem 1992;35:4270-8
- Herbst KL. Gonadotropin-releasing hormone antagonists. Curr Opin Pharmacol 2003;3:660-6
- Huhtainemi I, White R, McArdle CA, Persson B-E. Will GnRH antagonists improve prostate cancer treatment? Trends Endocrinol Metabol 2008;20:43-50
- Debruyne F, Gres AA, Arustamov DL. Placebo-controlled dose-ranging phase 2 study of subcutaneously administered LHRH antagonist cetrorelix in patients with symptomatic benign prostatic hyperplasia. Eur Urol 2008;54:170-7
- Kovács M, Szepesházi K, Schally AV. Endocrine and antineoplastic effects of antagonistic and cytotoxic analogs of luteinising hormone-releasing hormone. In: Kovács M, Merchenhalter I, editors, Neuropeptides and peptide analogs. Research Signpost, Kerela, India; 2009. p. 33-57
- Weckermann D, Harzman R. Hormone therapy in prostate cancer: LHRH antagonists versus LHRH analogues. Eur Urol 2004;46:279-84
- Broqua P, Riviere PJ, Conn PM, Pharmacological profile of a new, potent, and long-acting gonadotropin-releasing hormone antagonist: degarelix. J Pharmacol Exp Ther 2002;301:95-102
- Ferring BV. GnRH antagonists. US5925730; 1999
- Bernd M, Kutscher B, Gunther E, Methods of treatment using novel LHRH antagonists having improved solubility properties. US20060281685; 2006
- Kissei Pharmaceutical Co., Ltd. Fused heterocyclic derivative, medicinal composition containing the same, and medicinal use thereof. EP1939204; 2008, WO2007046392; 2007
- Ardana Bioscience Ltd. Sustained release of microcrystalline peptide suspension. US20060229238; 2006
- Praecis Pharmaceutical, Inc. Pharmaceutical formulations for sustained drug delivery. WO2007022254; 2007
- AEterna Zentaris GmbH. Application of initial doses LHRH analogues and maintenance doses of LHRH antagonists for the treatment of hormone-dependent cancers and corresponding pharmaceutical kits. WO2008017664; 2008, US20080032935; 2008, EP1891964; 2008
- Balance Pharmaceutical, Inc. Nasal-spray formulation and method. US6958142; 2005
- AEterna Zentaris GmbH. Injectable solution of an LHRH antagonist. US7214662; 2007
- Edwards RG, Lobo R, Bouchard P. Time to revolutionize ovarian stimulation. Hum Reprod 1996;11:917-9
- Janssens RM, Lamback CB, Vermeiden JP, Dose-finding study of triptorelin acetate for prevention of premature LH surge in IVF: a prospective, randomized, double-blind, placebo-controlled study. Hum Reprod 2000;15:2333-40
- Tarlatzis BC, Fauser BC, Kolibianakis EM, GnRH antagonists in ovarian stimulation for IVF. Hum Reprod Update 2006;12:333-40
- Fauser BC, Devroey P, Macklon NS. Multiple birth resulting from ovarian stimulation for subfertility treatment. Lancet 2005;365:1807-16
- Verberg MF, Macklon NS, Nargund G, Mild ovarian stimulation for IVF. Hum Reprod Update 2009;15:13-29
- AEterna Zentaris GmbH. LHRH-antagonists in the treatment of fertility disorders. US7393834; 2008
- Mező G, Manea M, Szabó I, New derivatives of GnRH as potential anticancer therapeutic agents. Curr Med Chem 2008;15:2366-79
- Brawer MK. The evolution of hormonal therapy for prostatic carcinoma. Rev Urol 2001;3S:1-9
- Emons G, Gründker C, Günthert AR, GnRH antagonists in the treatment of gynecological and breast cancers. Endocr Relat Cancer 2003;10:291-9
- Keller G, Schally AV, Gaiser T, Receptors for luteinizing hormone releasing hormone (LHRH) expressed in human non-Hodgkin's lymphomas can be targeted for therapy with cytotoxic LHRH analogue AN-207. Eur J Cancer 2005;41:2196-202
- Gründker C, Günthert AR, Westphalen S, Emons G. Biology of the gonadotropin-releasing hormone system in gynecological cancers. Eur J Endocrinol 2002;146:1-14
- Leung PC, Choi JH. Endocrine signaling in ovarian surface epithelium and cancer. Hum Reprod Update 2007;13:143-62
- Conn PM, Crowley WF Jr. Gonadotropin-releasing hormone and its analogs. Annu Rev Med 1994;45:391-405
- Sealfon SC, Weinstein H, Millar RP. Molecular mechanisms of ligand interaction with the gonadotropin-releasing hormone receptor. Endocr Rev 1997;18:180-205
- Gründker C, Völker P, Günthert AR, Emons G. Antiproliferative signaling of LHRH in human endometrial and ovarian cancer cells through G-protein αi-mediated activation of phosphotyrosine phosphatase. Endocrinology 2001;142:2369-80
- Maudsley S, Davidson L, Pawson AJ, Gonadotropin-releasing hormone (GnRH) antagonists promote proapoptotic signaling in peripheral reproductive tumor cells by activating a Galphai-coupling state of the type I GnRH receptor. Cancer Res 2004;64:7533-44
- Gründker C, Schlotawa L, Viereck V, Antiproliferative effects of the GnRH antagonist cetrorelix and of GnRH-II on human endometrial and ovarian cancer cells are not mediated through the GnRH type I receptor. Eur J Endocrinol 2004;151:141-9
- Fister S, Günthert AR, Emons G, Gründker C. Gonadotropin-releasing hormone type II antagonists induce apoptotic death in human endometrial and ovarian cancer cells in vitro and in vivo. Cancer Res 2007;67:1750-6
- Nagy A, Schally AV, Armatis P, Cytotoxic analogs of luteinizing hormone-releasing hormone containing doxorubicin or 2-pyrrolinodoxorubicin, a derivative 500-1000 times more potent. Proc Natl Acad Sci USA 1996;93:7269-73
- Tulane Educational Fund. Targeted cytotoxic anthracycline analogs. US6184374; 2001
- AEterna Zentaris GmbH. Conjugates of disorazoles and their derivatives with cell-binding molecules, novel disorazole derivatives, processes of manufacturing and uses thereof. US20080090758; 2008
- Szabó I, Manea M, Orbán E, Development of an oxime bond containing daunorubicin-gonadotropin-releasing hormone-III conjugate as a potential anticancer drug. Bioconjug Chem 2009;20:656-65
- Tulane Educational Fund. LHRH antagonists. US5198533; 1993
- Reissmann T, Engel J, Kutscher B, The LHRH antagonist Cetrorelix. Drugs Future 1994;19:228-37
- AEterna Zentaris GmbH. Preparation and use of oligopeptide lyophilisate for gonad protection. US6867191; 2005
- AEterna Zentaris GmbH. Method for producing steril suspensions or lyophilisates of poorly soluble basic peptide complexes, pharmaceutical formulations containing the same, and use thereof as medicaments. WO2006069641; 2006
- Asta Medica Aktiengesellschaft. Immobilized and activity-stabilized complexes of LHRH antagonists and processes for their preparation. US6022860; 1998
- Matikainen T, Ding YQ, Vergara M, Differing responses of plasma bioactive and immunoreactive follicle-stimulating hormone and luteinizing hormone to gonadotropin-releasing hormone antagonist and agonist treatments in postmenopausal women. J Clin Endocrinol 1992;7:820-5
- Olivennes F, Cuncha-Filho JS, Fanchin R, The use of GnRH antagonists in ovarian stimulation. Hum Reprod Update 2002;8:279-90
- Gonzalez-Barcena D, Alvarez RB, Ochoa EP, Treatment of uterine leiomyomas with luteinizing hormone-releasing hormone antagonist Cetrorelix. Hum Reprod 1997;12:2028-35
- Comaru-Schally AM, Brannan W, Schally AV, Efficacy and safety of luteinizing hormone-releasing hormone antagonist cetrorelix in the treatment of symptomatic benign prostatic hyperplasia. J Clin Endocrinol Metab 1998;83:3826-31
- Telegdy G, Tanaka M, Schally AV. Effects of the LHRH antagonist Cetrorelix on the brain function in mice. Neuropeptides 2009;43:229-34
- AEterna Zentaris GmbH. Treatment of dementia and neurodegenerative diseases with intermediate doses of LHRH antagonists. US7288517; 2007
- Ben-Josef E, Yang SY, Ji TH, Hormone-refractory prostate cancer cells expresses functional follicle-stimulating hormone receptor (FSHR). J Urol 1999;161:970-6
- Praecis Pharmaceuticals, Inc. Methods for treating FSH related conditions with GnRH antagonists. US7109171; 2007
- Tomera K, Gleason D, Gittelman M, The gonadotropin-releasing hormon antagonist abarelix depot versus luteinizing hormone releasing hormone agonists leuprolide or goserelin: initial results of endocrinological and biochemical efficacies in patients with prostate cancer. J Urol 2001;165:1585-9
- Wong SL, Lau DT-W, Baughman SA, Pharmacokinetics and pharmacodynamics of abarelix, a gonadotropin releasing hormone (GnRH) antagonists after subcutaneous, continuous infusion in patients with prostate cancer. Clin Pharmacol Ther 2003;73:304-11
- Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery. US5968895; 1999
- Wong SL, Lau DT-W, Baughman SA, Pharmacokinetics and pharmacodynamics of a novel depot formulation of abarelix, a gonadotropin releasing hormone (GnRH) antagonists, in healthy men ages 50 to 75. J Clin Pharmacol 2004;44:495-502
- Van Poppel H, Nilsson S. Testosteron surge: rationale for gonadotropin-releasing hormon blockers? Urology 2008;71:1001-6
- Steiner MS, Veverka KA. Composition comprising a SARM and GnRH agonist or an GnRH antagonist, and methods of use thereof. US20060287282; 2006
- Felberbaum R, Diedrich K. Ovarian stimulation for in-vitro fertilization/intracytoplasmic sperm injection with gonadotrophins and gonadotrophin-releasing hormone analogues: agonists and antagonists. Hum Reprod 1999;14:207-21
- Meldrum DR, Scott RT, Levy MJ, Oral contraceptive pretreatment in women undergoing controlled ovarian stimulation in ganirelix acetate cycles may, for a subset of patients, be associated with low serum luteinizing hormone levels, reduced ovarian response to gonadotropins and early pregnancy loss. Fertil Steril 2009;91:1963-5
- Bellver J, Albert C, Lambarta E, Pellicer A. Early pregnancy loss in women stimulated with gonadotropin-releasing hormone antagonist protocols according to oral contraceptive pretreatment. Fertil Steril 2007;87:1098-101
- Meldrum DR, Cassidenti DL, Rosen GF, Oral contraceptive pretreatment and half dose of ganirelix does not excessively suppress LH and may be an excellent choice for scheduling IUI cycles. J Assist Reprod Genet 2008;25:417-20
- Rivier J. GnRH analogues towards the next millenium. In: Lunenfeld B, editor, GnRH Analogues – TheState of Art at the Millenium; Parthenon Publishing: Carnforth, UK; 1999. p. 31-45
- Haviv F, Fitzpatrick TD, Nichols CJ, The effect of of NMeTyr5 substitution in luteinizing hormone-releasing hormone antagonists. J Med Chem 1993;36:928-33
- Ferring BV. GnRH antagonists being modified in positions 5 and 6. WO1998046634; 1998, US6214798; 2001
- Doehn C, Sommerauer M, Jocham D. Drug evaluation: degarelix – a potential new therapy for prostate cancer. IDrugs 2006;9:565-72
- Klotz L, Boccon-Gibod L, Shore ND, The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in prostate cancer patients. BJU Int 2008;102:1531-8
- Persson B-E, Olesen TK, Jensen J-K. Degarelix: a new approach for the treatment of prostate cancer. Neuroendocrinology 2009;90:235-44
- Doehn C, Sommerauer M, Jocham D. Degarelix and its therapeutic potential in the treatment of prostate cancer. Clin Intervent Aging 2009;4:215-23
- Samant MP, Gulyas J, Hong DJ, Iterative approach to the discovery of novel degarelix analogues: substitutions at positions 3, 7, and 8. Part II. J Med Chem 2005;48:4851-60
- Samant MP, Gulyas J, Hong DJ, Synthesis, in vivo and in vitro biological activity of novel azaline B analogs. Bioorg Med Chem Lett 2005;15:2894-7
- AEterna Zentaris GmbH. LHRH antagonists having improved solubility properties. US7148195; 2006
- AEterna Zentaris GmbH. Use of LHRH antagonists for the treatment of lower urinary tract symptoms, in particular overactive bladder and/or detrusor overactivity. EP1967202; 2008
- Pelletier JC, Chengalvala M, Cottom J, 2-Phenyl-4-piprazinylbenzimidazoles: Orally active inhibitors of the gonadotropin releasing (GnRH) receptor. Bioorg Med Chem 2008;16:6617-40
- Heitman LH, Ijzerman AP. G protein-coupled receptors of the hypothalamic-pituitary-gonadal axis: a case for GnRH, LH, FSH, and GPR54 receptor ligands. Med Res Rev 2008;28:975-1011
- Betz SF, Zhu YF, Chen C, Struthers RS. Non-peptide gonadotropin-releasing hormone receptor antagonists. J Med Chem 2008;51:3331-48
- Neurocrine Biosciences, Inc. Gonadotropin-releasing hormone receptor antagonists and methods relating thereto. WO2005007633; 2005, US7229995; 2007
- Chen C, Wu D, Guo Z, Discovery of sodium R-(+)-4-{2-[5-(2-fluoro-3-methoxyphenyl)-3-(2-fluoro-6-[trifluoromethyl]benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenylethylamino}butyrate (elagolix), a potent and orally available nonpeptide antagonist of the human gonadotropin-releasing hormone receptor. J Med Chem 2008;51:7478-85
- Struthers RS, Nicholls AJ, Grundy J, Suppression of gonadotropins and estradiol in premenopausal women by oral administration of the nonpeptide gonadotropin-releasing hormone antagonist elagolix. J Clin Endocrinol Metab 2009;94:545-51